Enovix Stock Sinks to New Low as JPMorgan Turns Bearish on Smartphone Battery Ramp
Published on 07/26/2026 at 02:10 | Redaktion boerse-global.de
The battery technology company Enovix closed Friday at €3.44, marking a fresh 52-week trough that extends a punishing sell-off. The stock has now shed roughly 72 percent of its value over the past twelve months, with Friday alone accounting for a near-10 percent decline and the monthly drop exceeding one-third.
Technical indicators are flashing extreme oversold conditions. The relative strength index sits at 28.9, deep in textbook oversold territory, while the share price trades roughly 36 percent below its 50-day moving average and nearly 47 percent beneath the 200-day average. Yet in this case, oversold has not translated into a bounce — a pattern that often signals the market has stopped anticipating a turnaround.
Analyst Divergence Widens as JPMorgan Pulls Its Price Target
The selling pressure has been amplified by a sharp split on Wall Street. JPMorgan recently downgraded Enovix to "Underweight" and removed its price target entirely, with analyst Bill Peterson citing slower-than-expected production ramp at Honor, the company's key smartphone customer, and the risk that competing battery makers could close the energy-density gap.
Other firms have taken a more measured approach. Craig Hallum lowered its target from $10 to $8 but maintained a "Buy" rating. Benchmark cut from $25 to $15 while keeping "Buy," and Oppenheimer reduced from $24 to $21 with an "Outperform" call. Weiss Ratings, however, reaffirmed its "Sell (e+)" stance. The average analyst price target still stands at €11.52 — more than 235 percent above the current price — a gap that either reflects stale estimates or suggests the market is pricing in operational disappointment that the models have yet to capture.
Should investors sell immediately? Or is it worth buying Enovix?
Apple COO Hire Fails to Stem the Tide
Enovix recently announced that Dr. Michael Vyvoda, a former Apple executive who helped scale AirPods production to high volume, will join as chief operating officer effective July 29, 2026. The news initially sent shares up as much as 17.1 percent in premarket trading, but the rally evaporated almost immediately.
The swift reversal is itself a warning. When a stock cannot hold gains on unambiguously positive news, it signals concerns that go deeper than management appointments. Vyvoda will oversee manufacturing, supply chain and operations engineering globally, reporting directly to CEO Dr. Raj Talluri. But investors appear skeptical that a single executive can resolve the execution risk surrounding Enovix's Korea-focused pipeline, which the company values at over $130 million.
Earnings Date Set as Production Progress Continues
Enovix will report second-quarter results on August 12. The company has made tangible operational strides: first-quarter revenue reached $7.6 million, up 49 percent year-over-year and above guidance, marking the sixth consecutive quarter of positive gross profit. The Korea battery pipeline grew to more than $130 million, and commercial production of silicon-anode batteries for smart eyewear began after an initial order of roughly 50,000 units.
Enovix at a turning point? This analysis reveals what investors need to know now.
Yet these milestones have done little to arrest the decline. With an annualized 30-day volatility of nearly 80 percent and a market capitalization of roughly €898 million, Enovix has become a stock where sentiment trumps fundamentals. The narrative has shifted from silicon-anode disruptor to a struggling small-cap that must still prove its production ramp is real.
The upcoming earnings report will test whether the current sell-off represents capitulation or the next leg lower. Given the stock's tendency to give back positive news almost as quickly as it arrives, the market is demanding concrete evidence — not promises. Until the production ramp translates into credible, reliable guidance, the path of least resistance for this stock remains downward, even from levels that already look historically depressed.
Ad
Enovix Stock: New Analysis - 26 July
Fresh Enovix information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
